All news


IN2LifeSciences project concludes successful third round

logo in2lifesciences

[Press release] On February 1, the fourth and final call for incentives has opened, offering SMEs the chance to speed up their innovation. Life Sciences SMEs are invited to apply until May 4, 2014. A total of 164 incentives have been granted during the first three calls; 53 Collaboration, 29 Insight, 82 Meet and Greet. SMEs that wish to take part in the project can contact their Regional Access Broker or fill out an online application form.


A new member joins in the cluster: Korilog

KORILOG is a publisher of scientific software for sequence data analysis. The company offers a range of software based on KLAST, the new high-performance sequence similarity search technology created by Korilog and the Rennes INRIA1-IRISA2 research center. Through the network of Atlanpole Biotherapies, Korilog wants to accelerate its development by taking part in projects with the network members, both private and academic.


Two DHU projects certified in Nantes

To better coordinate care, teaching and research, to strengthen relations between hospital and university, to share innovation more efficiently... These are some of the objectives of the two university hospital departments (DHU), which an international jury selected in Nantes.


AAA receives orphan drug designation from FDA and EMA for Gallium-68 DOTATATE

Advanced Accelerator Applications

Advanced Accelerator Applications announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE. The orphan drug designation has been granted by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use of Gallium-68 DOTATATE as a diagnostic agent for the management of Gastro-Entero- Pancreatic Neuroendocrine Tumors (GEP-NETs).


Creation of Horama


Horama is a biotechnology company specializing in the development of innovative gene therapy products for the treatment of retinopathies, serious and “orphan” diseases, resulting in loss of visual acuity or blindness.


Valneva: Aeras Initiates Phase II Clinical T rial of A Tuberculosis Vaccine Candidate U sing IC31 ® A djuvant


[Press release] European Biotech company Valneva is pleased to distribute the following press release issued by Aeras about the initiation of a Phase II randomized clinical trial for their tuberculosis (TB) vaccine candidate Aeras-404 using Valneva's IC31® proprietary adjuvant.


Cédric Le May was awarded the Daniel Steinberg prize of the best scientific publication

Crédits photo : Presse Océan - Olivier Lanrivain

Researcher at the thorax Institute, Cédric Le May was awarded the Daniel Steinberg prize of the best 2013 scientific publication.